Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/β-Catenin Signaling in Ovarian Cancer.

Xiaohong Ruan | Aibin Liu | Meigong Zhong | Jihong Wei | Weijian Zhang | Yingrou Rong | Wanmin Liu | Mingwei Li | Xingrong Qing | Gaowen Chen | Ronggang Li | Yuehua Liao | Qiongru Liu | Xin Zhang | Dong Ren | Yifeng Wang
Molecular therapy oncolytics | 2019

Leucine-rich-repeat-containing G protein-coupled receptors (LGRs) have been widely found to be implicated with development and progression in multiple cancer types. However, the clinical significance and biological functions of LGR6 in ovarian cancer remains unclear. In this study, LGR6 expression was mainly examined by immunohistochemistry. Functional assays in vitro and animal experiments in vivo were carried out to explore the effect of LGR6 on cancer stem cell (CSC) characteristics and chemotherapeutic responses in ovarian cancer cells. Luciferase assays and GSEA were used to discern the underlying mechanisms contributing to the roles of LGR6 in ovarian cancer. Here, we reported that LGR6 was upregulated in ovarian cancer, which positively correlated with poor chemotherapeutic response and progression survival in ovarian cancer patients. Loss-of-function assays showed that downregulating LGR6 abrogated the CSC-like phenotype and chemoresistance in vitro. More importantly, silencing LGR6 improved the chemoresistance of ovarian cancer cells to cisplatin in vivo. Mechanistic investigation further revealed that silencing LGR6 inhibited stemness and chemoresistance by repressing Wnt/β-catenin signaling. Collectively, our results uncover a novel mechanism contributing to LGR6-induced chemotherapeutic resistance in ovarian cancer, providing the evidence for LGR6 as a potential therapeutic target in ovarian cancer.

Pubmed ID: 31193124

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Molecular Signatures Database (tool)

RRID:SCR_016863

Collection of annotated gene sets for use with Gene Set Enrichment Analysis (GSEA) software.

View all literature mentions

SK-OV-3 (tool)

RRID:CVCL_0532

Cell line SK-OV-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

A2780 (tool)

RRID:CVCL_0134

Cell line A2780 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

OVCAR-3 (tool)

RRID:CVCL_0465

Cell line OVCAR-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

Crl:NU(NCr)-Foxn1nu (tool)

RRID:IMSR_CRL:490

Mus musculus with name Crl:NU(NCr)-Foxn1nu from IMSR.

View all literature mentions